Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31320124 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL21326520 | 0.85 | KEAP1 (0.46) | ALDH1A1KDM4EL3MBTL1HPGDKMT2A | |
| SCHEMBL21349700 | 0.83 | KDM4E (0.53) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1GAA | |
| SCHEMBL21349339 | 0.82 | KDM4E (0.47) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL28906480 | 0.79 | PLA2G2A (0.40) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1GAA | |
| SCHEMBL28906484 | 0.76 | MAPT (0.42) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL21551592 | 0.76 | PLA2G2A (0.43) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL30931812 | 0.76 | PLA2G2A (0.43) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL391203 | 0.75 | POLB (0.50) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL21349340 | 0.72 | KDM4E (0.51) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024240108-A1 | ARYL UREA PARP1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-115304623-A | Pyrimido-cyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2021-03-16 | — | — | US | disclosed |
| EP-3535267-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-30 | — | — | EP | disclosed |
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | ALDH1A1 404/4885KDM4E 1504/4885SMN1; SMN2 800/4885 |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | ALDH1A1 317/4885KDM4E 1414/4885SMN1; SMN2 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.